Interview with Guillaume DRIANNO, General Manager, Servier Brasil
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
Address: Estrada dos Bandeirantes, 4211
22775-113 – Rio de Janeiro – RJ,Brazil
Tel: (55 21) 2142-1414
Web: http://www.servier.com.br/
Servier Brasil is the first subsidiary of the Servier in Latin America, being present in the country for more than 35 years. In 2001 it opened an International Center of Therapeutic Research in Rio de Janeiro demonstrating a commitment to strengthening their presence in Brazil and Latin America.
Since the opening of its new modern factory in Jacarepaguá, Rio de Janeiro, Servier Brazil has been preparing to become a major supplier of Servier’s innovative drugs to the Brazilian and Latin American market.
Valdoxan, Procoralan 7,5mg, Coversyl, Coversyl Plus, Natrilix SR, Daflon 500, Diamicron MR, Protos, Vastarel, Arcalion , Trivastal Retard, Muphoran, Locabiotal .
When we met Servier Brazil five years ago the company had major ambitions: ‘grow more than 10% for the five following years’. How have these expectations turned out to be?…
Mauro Loch, general manager of Amgen Brazil, documents the eye-catching turnaround of the affiliate since the beginning of his tenure and provides insights into the company’s unique positioning in Brazil,…
Haig Yeghiaian, country manager of LEO Pharma Brazil, details his strategic mission and objectives since he took over the helm of the affiliate in November 2016 as well as the…
In an exclusive interview, Minister of Health of Brazil Ricardo Barros provides insights into his main achievements since being appointed in May 2016 and his key priorities to further improve…
Fabio Bussinger, partner-director of the Pharmaceutical Institute of Operational Governance (IFGO) in Brazil, documents the market needs that prompted him to set up Benchmarking Operational Competitiveness (BCO) Farma, a long-awaited…
Lauro Moretto, Emeritus President of the Brazilian Academy of Pharmaceutical Sciences and former Executive Vice-President of Sindusfarma provides insights into the main changes that have impacted Brazil’s pharmaceutical field over…
In an exclusive interview, Jarbas Barbosa da Silva, Director-President of the Brazilian Health Regulatory Agency (ANVISA), discusses some of the key specificities of the Brazilian market and highlights some of…
Dr. Wilson Pedreira, executive director of the Oncology and Hematology Center of the Albert Einstein Philanthropic Society in Brazil provides insights into the innovative healthcare model implemented in this cutting…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re…
Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is…
When we interviewed you four years ago, you gave us a picture of the industry. How has that picture changed since then? We can start with the regulatory picture. In…
Hypermarcas is a huge, diversified corporation that sells everything from shampoo, to medicine. Would you consider it more of a consumer goods company that happens to sell pharmaceuticals, or the…
See our Cookie Privacy Policy Here
